Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 7, 2015, Pages 8494-8499

  Bi, Yiliang ^a   Min, Min ^a   Shen, Wei ^a   Deng, Pei ^a   Du, Qiupeng ^a   Dong, Mingjie ^a   Liu, Yan ^a  

^a Beijing 307 Hospital   (China)

Author keywords

High sensitivity C reaction protein; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Non insulin dependent diabetes mellitus

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; AGED; BLOOD; CHI SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; UPREGULATION; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 85012991842     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Stahl HD. Use of high-sensitivity CRP to predict first cardiovascular events. Lancet 2007; 369: 1259-1260.
2. Choi JH, Cho DK, Song YB, Hahn JY, Choi S, Gwon HC, Kim DK, Lee SH, Oh JK and Jeon ES. Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery. Heart 2010; 96: 56-62.
3. Coppola G, Corrado E, Muratori I, Tantillo R, Vitale G, Lo Coco L and Novo S. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol 2006; 106: 16-20.
4. Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS, Hu J, Yang ZK, Ding FH, Chen QJ, Lou S, Shen J, Fang DH and Shen WF. Value of serum glycated albumin and high-sensitivity C-re-active protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006; 5: 27.
5. de Luca C and Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008; 582: 97-105.
6. Lu B, Yang Y, Yang Z, Feng X, Wang X, Zhang Z and Hu R. Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity. Cardiovasc Diabetol 2010; 9: 92.
7. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M and George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379.
8. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ and Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-32353.
9. Wang CL, Liang L, Fu JF, Zou CC, Hong F, Xue JZ, Lu JR and Wu XM. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008; 14: 1598-1602.
10. Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ and Chen SY. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003; 9: 1106-1110.
11. Jansen PL. Non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2004; 16: 1079-1085.
12. Cortez-Pinto H and Camilo ME. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004; 18: 1089-1104.
13. Ong JP and Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16, vii.
14. Serfaty L and Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 2008; 34: 634-637.
15. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ and Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974.
16. Krupinski J, Turu MM, Slevin M and Martinez-Gonzalez J. Carotid plaque, stroke pathogenesis, and CRP: treatment of ischemic stroke. Curr Cardiol Rep 2008; 10: 25-30.
17. Meisinger C, Heier M, von Scheidt W and Kuch B. Admission C-reactive protein and short-as well as long-term mortality in diabetic versus non-diabetic patients with incident myocardial infarction. Clin Res Cardiol 2010; 99: 817-823.
18. Boger CA, Gotz A, Stubanus M, Banas B, Deinzer M, Kruger B, Holmer SR, Schmitz G, Riegger GA and Kramer BK. C-reactive protein as predictor of death in end-stage diabetic nephropathy: role of peripheral arterial disease. Kidney Int 2005; 68: 217-227.
19. Anzai T, Yoshikawa T, Takahashi T, Maekawa Y, Okabe T, Asakura Y, Satoh T, Mitamura H and Ogawa S. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 2003; 99: 47-53.
20. Gonzalez MA and Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003; 115 Suppl 8A: 99S-106S.
21. Arsenault BJ, Earnest CP, Despres JP, Blair SN and Church TS. Obesity, coffee consumption and CRP levels in postmenopausal overweight/obese women: importance of hormone replacement therapy use. Eur J Clin Nutr 2009; 63: 1419-1424.
22. Wee CC, Mukamal KJ, Huang A, Davis RB, McCarthy EP and Mittleman MA. Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring) 2008; 16: 875-880.